PortalPublikationenImpact of donor-derived CD34 + infused cell dose on outcomes...

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

Standard

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. / Czerw, Tomasz; Iacobelli, Simona; Malpassuti, Vittoria; Koster, Linda; Kröger, Nicolaus; Robin, Marie; Maertens, Johan; Chevallier, Patrice; Watz, Emma; Poiré, Xavier; Snowden, John A; Kuball, Jürgen; Kinsella, Francesca; Blaise, Didier; Reményi, Péter; Mear, Jean-Baptiste; Cammenga, Jörg; Rubio, Marie Thérèse; Maury, Sebastien; Daguindau, Etienne; Finnegan, Damian; Hayden, Patrick; Hernández-Boluda, Juan Carlos; McLornan, Donal; Yakoub-Agha, Ibrahim.

in: BONE MARROW TRANSPL, Jahrgang 57, Nr. 2, 02.2022, S. 261-270.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Czerw, T, Iacobelli, S, Malpassuti, V, Koster, L, Kröger, N, Robin, M, Maertens, J, Chevallier, P, Watz, E, Poiré, X, Snowden, JA, Kuball, J, Kinsella, F, Blaise, D, Reményi, P, Mear, J-B, Cammenga, J, Rubio, MT, Maury, S, Daguindau, E, Finnegan, D, Hayden, P, Hernández-Boluda, JC, McLornan, D & Yakoub-Agha, I 2022, 'Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 57, Nr. 2, S. 261-270. https://doi.org/10.1038/s41409-021-01540-2

APA

Czerw, T., Iacobelli, S., Malpassuti, V., Koster, L., Kröger, N., Robin, M., Maertens, J., Chevallier, P., Watz, E., Poiré, X., Snowden, J. A., Kuball, J., Kinsella, F., Blaise, D., Reményi, P., Mear, J-B., Cammenga, J., Rubio, M. T., Maury, S., ... Yakoub-Agha, I. (2022). Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 57(2), 261-270. https://doi.org/10.1038/s41409-021-01540-2

Vancouver

Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M et al. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2022 Feb;57(2):261-270. https://doi.org/10.1038/s41409-021-01540-2

Bibtex

@article{5d7fca58c7f143969aa5095cd163c7e5,
title = "Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT",
abstract = "The optimal CD34 + cell dose in the setting of RIC allo-HCT for myelofibrosis (MF) remains unknown. We retrospectively analyzed 657 patients with primary or secondary MF transplanted with use of peripheral blood (PB) stem cells after fludarabine/melphalan or fludarabine/busulfan RIC regimen. Median patient age was 58 (range, 22-76) years. Donors were HLA-identical sibling (MSD) or unrelated (UD). Median follow-up was 46 (2-194) months. Patients transplanted with higher doses of CD34 + cells (>7.0 × 106/kg), had an increased chance of achievement of both neutrophil (hazard ratio (HR), 1.46; P < 0.001) and platelet engraftment (HR, 1.43; P < 0.001). In a model with interaction, for patients transplanted from a MSD, higher CD34 + dose was associated with improved overall survival (HR, 0.63; P = 0.04) and relapse-free survival (HR, 0.61; P = 0.02), lower risk of non-relapse mortality (HR, 0.57; P = 0.04) and higher rate of platelet engraftment. The combined effect of higher cell dose and UD was apparent only for higher neutrophil and platelet recovery rate. We did not document any detrimental effect of high CD34 + dose on transplant outcomes. More bulky splenomegaly was an adverse factor for survival, engraftment and NRM. Our analysis suggests a potential benefit for MF patients undergoing RIC PB-allo-HCT receiving more than 7.0 × 106/kg CD34 + cells.",
author = "Tomasz Czerw and Simona Iacobelli and Vittoria Malpassuti and Linda Koster and Nicolaus Kr{\"o}ger and Marie Robin and Johan Maertens and Patrice Chevallier and Emma Watz and Xavier Poir{\'e} and Snowden, {John A} and J{\"u}rgen Kuball and Francesca Kinsella and Didier Blaise and P{\'e}ter Rem{\'e}nyi and Jean-Baptiste Mear and J{\"o}rg Cammenga and Rubio, {Marie Th{\'e}r{\`e}se} and Sebastien Maury and Etienne Daguindau and Damian Finnegan and Patrick Hayden and Hern{\'a}ndez-Boluda, {Juan Carlos} and Donal McLornan and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = feb,
doi = "10.1038/s41409-021-01540-2",
language = "English",
volume = "57",
pages = "261--270",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

AU - Czerw, Tomasz

AU - Iacobelli, Simona

AU - Malpassuti, Vittoria

AU - Koster, Linda

AU - Kröger, Nicolaus

AU - Robin, Marie

AU - Maertens, Johan

AU - Chevallier, Patrice

AU - Watz, Emma

AU - Poiré, Xavier

AU - Snowden, John A

AU - Kuball, Jürgen

AU - Kinsella, Francesca

AU - Blaise, Didier

AU - Reményi, Péter

AU - Mear, Jean-Baptiste

AU - Cammenga, Jörg

AU - Rubio, Marie Thérèse

AU - Maury, Sebastien

AU - Daguindau, Etienne

AU - Finnegan, Damian

AU - Hayden, Patrick

AU - Hernández-Boluda, Juan Carlos

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/2

Y1 - 2022/2

N2 - The optimal CD34 + cell dose in the setting of RIC allo-HCT for myelofibrosis (MF) remains unknown. We retrospectively analyzed 657 patients with primary or secondary MF transplanted with use of peripheral blood (PB) stem cells after fludarabine/melphalan or fludarabine/busulfan RIC regimen. Median patient age was 58 (range, 22-76) years. Donors were HLA-identical sibling (MSD) or unrelated (UD). Median follow-up was 46 (2-194) months. Patients transplanted with higher doses of CD34 + cells (>7.0 × 106/kg), had an increased chance of achievement of both neutrophil (hazard ratio (HR), 1.46; P < 0.001) and platelet engraftment (HR, 1.43; P < 0.001). In a model with interaction, for patients transplanted from a MSD, higher CD34 + dose was associated with improved overall survival (HR, 0.63; P = 0.04) and relapse-free survival (HR, 0.61; P = 0.02), lower risk of non-relapse mortality (HR, 0.57; P = 0.04) and higher rate of platelet engraftment. The combined effect of higher cell dose and UD was apparent only for higher neutrophil and platelet recovery rate. We did not document any detrimental effect of high CD34 + dose on transplant outcomes. More bulky splenomegaly was an adverse factor for survival, engraftment and NRM. Our analysis suggests a potential benefit for MF patients undergoing RIC PB-allo-HCT receiving more than 7.0 × 106/kg CD34 + cells.

AB - The optimal CD34 + cell dose in the setting of RIC allo-HCT for myelofibrosis (MF) remains unknown. We retrospectively analyzed 657 patients with primary or secondary MF transplanted with use of peripheral blood (PB) stem cells after fludarabine/melphalan or fludarabine/busulfan RIC regimen. Median patient age was 58 (range, 22-76) years. Donors were HLA-identical sibling (MSD) or unrelated (UD). Median follow-up was 46 (2-194) months. Patients transplanted with higher doses of CD34 + cells (>7.0 × 106/kg), had an increased chance of achievement of both neutrophil (hazard ratio (HR), 1.46; P < 0.001) and platelet engraftment (HR, 1.43; P < 0.001). In a model with interaction, for patients transplanted from a MSD, higher CD34 + dose was associated with improved overall survival (HR, 0.63; P = 0.04) and relapse-free survival (HR, 0.61; P = 0.02), lower risk of non-relapse mortality (HR, 0.57; P = 0.04) and higher rate of platelet engraftment. The combined effect of higher cell dose and UD was apparent only for higher neutrophil and platelet recovery rate. We did not document any detrimental effect of high CD34 + dose on transplant outcomes. More bulky splenomegaly was an adverse factor for survival, engraftment and NRM. Our analysis suggests a potential benefit for MF patients undergoing RIC PB-allo-HCT receiving more than 7.0 × 106/kg CD34 + cells.

U2 - 10.1038/s41409-021-01540-2

DO - 10.1038/s41409-021-01540-2

M3 - SCORING: Journal article

C2 - 34853433

VL - 57

SP - 261

EP - 270

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -